Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

Share this content:
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.

Men diagnosed with low- or intermediate-risk prostate cancer were willing to sacrifice some survival time in exchange for improvements in quality of life (QoL), according to findings from the COMPARE trial, which were presented at the 2018 National Cancer Research Institute (NCRI) Conference, Glasgow, United Kingdom.1

Specifically, surveyed men were willing to trade off on survival for fewer further treatments following initial therapy, a greater chance of maintaining urinary continence, and a higher chance of maintaining erectile function.

The study was presented by Hashim Ahmed, PhD, chair and professor of urology, Imperial College London, and chair of NCRI's Prostate Cancer Clinical Studies Group.

The COMPARE study used a discrete choice experiment (DCE) designed to elicit patient preferences for managing localized prostate cancer. The DCE included variables such as type of treatment, return to day-to-day activities, sexual function, urinary function, further treatment, and cancer-specific survival over 10 to 15 years.

According to Neha Vapiwala, MD, associate professor of radiation oncology at the Abramson Cancer Center at University of Pennsylvania, men diagnosed with low- or intermediate-risk prostate cancer are typically presented with a variety of treatment options. For some men, active surveillance may be recommended. Others may undergo surgery with either traditional open prostatectomy or robotic-assisted prostatectomy, or men may undergo radiation with relatively less-invasive (compared with surgery) brachytherapy or noninvasive external beam radiation.

In the COMPARE study, the DCE was completed by 634 men within a week of diagnosis of localized disease. The mean patient age was 67.7. The men were presented with 2 hypothetical treatments that varied in terms of their likely effect on survival, incontinence, impotence, recovery time, and chance of needing further treatment. The men had to pick which of the 2 scenarios they would choose; this choice was presented several times with different combinations of hypothetical survival benefit with degree of side effects.

The type of treatment offered was not observed to affect men's preferences, except that patients with low- or intermediate-risk disease (74%) preferred active surveillance to radical therapy.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs